Three Reasons to Avoid MED and One Stock to Buy Instead

StockStory12-03

Three Reasons to Avoid MED and One Stock to Buy Instead What a brutal six months it’s been for Medifast. The stock has dropped 20.6% and now trades at $19.84, rattling many shareholders. This may ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488948282?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zdquxXqvluqz4pjwDBJIkQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/add46d51010cdba90e56c97fa248b9f6","is_english":true,"pubTime":"2024-12-03 16:08","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2488948282","market":"us","top_or_hot":-1,"title":"Three Reasons to Avoid MED and One Stock to Buy Instead","media":"StockStory","content":"<div>\n<p>Three Reasons to Avoid MED and One Stock to Buy Instead \n \n\nWhat a brutal six months it’s been for Medifast. The stock has dropped 20.6% and now trades at $19.84, rattling many shareholders. This may ...</p>\n\n<a href=\"https://finance.yahoo.com/news/three-reasons-avoid-med-one-080844144.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three Reasons to Avoid MED and One Stock to Buy Instead</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree Reasons to Avoid MED and One Stock to Buy Instead\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-03 16:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/three-reasons-avoid-med-one-080844144.html><strong>StockStory</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Three Reasons to Avoid MED and One Stock to Buy Instead \n \n\nWhat a brutal six months it’s been for Medifast. The stock has dropped 20.6% and now trades at $19.84, rattling many shareholders. This may ...</p>\n\n<a href=\"https://finance.yahoo.com/news/three-reasons-avoid-med-one-080844144.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4183","symbol_name":"个人用品","start_time":0,"source_url":"https://finance.yahoo.com/news/three-reasons-avoid-med-one-080844144.html","article_id":"2488948282","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zdquxXqvluqz4pjwDBJIkQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/add46d51010cdba90e56c97fa248b9f6"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488948282","pubTimestamp":1733213324,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"What a brutal six months it’s been for Medifast. The stock has dropped 20.6% and now trades at $19.84, rattling many shareholders. This may have investors wondering how to approach the situation.Is there a buying opportunity in Medifast, or does it present a risk to your portfolio?See what our analysts have to say in our full research report, it’s free.Despite the more favorable entry price, we're cautious about Medifast. Here are three reasons why MED doesn't excite us and a stock we'd rather own.Known for its Optavia program that combines portion-controlled meal replacements with coaching, Medifast  has a broad product portfolio of bars, snacks, drinks, and desserts for those looking to lose weight or consume healthier foods.A company’s long-term sales performance can indicate its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Over the last three years, Medifast’s demand was weak and its revenue declined by 21.9% per year. This ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4183":"个人用品","BK4532":"文艺复兴科技持仓","MED":"快验保"},"translate_title":"避免MED的三个理由和一只值得购买的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MED":1},"content_text":"Three Reasons to Avoid MED and One Stock to Buy Instead \n \n\nWhat a brutal six months it’s been for Medifast. The stock has dropped 20.6% and now trades at $19.84, rattling many shareholders. This may have investors wondering how to approach the situation. \nIs there a buying opportunity in Medifast, or does it present a risk to your portfolio? \nSee what our analysts have to say in our full research report, it’s free. \nDespite the more favorable entry price, we're cautious about Medifast. Here are three reasons why MED doesn't excite us and a stock we'd rather own. \nWhy Do We Think Medifast Will Underperform? \nKnown for its Optavia program that combines portion-controlled meal replacements with coaching, Medifast (NYSE:MED) has a broad product portfolio of bars, snacks, drinks, and desserts for those looking to lose weight or consume healthier foods. \n1. Revenue Spiraling Downwards\nA company’s long-term sales performance can indicate its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Over the last three years, Medifast’s demand was weak and its revenue declined by 21.9% per year. This fell short of our benchmarks and is a sign of poor business quality. \n2. EPS Trending Down\nWe track the change in earnings per share (EPS) because it highlights whether a company’s growth is profitable. \nSadly for Medifast, its EPS declined by more than its revenue over the last three years, dropping 63.3% annually. This tells us the company struggled because its fixed cost base made it difficult to adjust to shrinking demand. \n\nAs long-term investors, the risk we care about most is the permanent loss of capital, which can happen when a company goes bankrupt or raises money from a disadvantaged position. This is separate from short-term stock price volatility, something we are much less bothered by. \nFinal Judgment\nMedifast doesn’t pass our quality test. Following the recent decline, the stock trades at 40.1x forward price-to-earnings (or $19.84 per share). This valuation tells us a lot of optimism is priced in - we think there are better stocks to buy right now. We’d suggest looking at The Trade Desk, the nucleus of digital advertising. \nStocks We Like More Than Medifast\nThe elections are now behind us. With rates dropping and inflation cooling, many analysts expect a breakout market to cap off the year - and we’re zeroing in on the stocks that could benefit immensely. \nTake advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. \nStocks that made our list in 2019 include now familiar names such as Nvidia (+2,691% between September 2019 and September 2024) as well as under-the-radar businesses like Comfort Systems (+783% five-year return). Find your next big winner with StockStory today for free.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488948282"}